
TSE:WELL
This summary was created by AI, based on 15 opinions in the last 12 months.
WELL Health Technologies, active in the Canadian healthcare sector, has garnered mixed reviews from experts. While the company is seen as well-positioned due to its focus on Canadian assets and consolidation of clinics, concerns linger regarding its large American assets, which some analysts believe are dragging down the stock. There is optimism surrounding the upcoming IPO of its technology business, Wellstar, which is expected to unlock significant value. However, challenges persist, such as a competitive regulatory environment and a perceived lack of execution. Despite its attractive valuation metrics, many experts highlight the need for patience and concrete progress on divesting non-core operations to reignite investor confidence.
The quarter was good. The question referenced was asking what it would take to get the stock moving more. We answered that debt and cash flow need to improve to get a higher valuation. We are comfortable with the outlook and current valuation, but it needs a catalyst to get its mojo back. We would be comfortable owning it but would not see the need to buy more if owned.
Unlock Premium - Try 5i Free
Expectations have been high since the beginning; founder's previous success was attributed to this name. Business has changed over time. Good job growing business. Revenue growth is there, profitability is not. Good investment banking client, as they raise money quite often, and so the analysts are favourable to it.
Great company. Management's done well on M&A front. Delayed financials, not a good sign; a US company they own is being investigated. Red flag. He still has faith in management. Watch the next month very carefully; further delay is a double-red flag, resolution would represent a very strong buying opportunity.
He is looking at it. It is very cheap and starting to move, with metrics looking pretty attractive now. It looks like we'll see a more focused company in the future. There was a bubble in the health tech sector but things are sorting themselves out and it looks good for investment. You could probably start buying.
Has a lid on it going back 3 years. There is no right or wrong answer, but when you're coming into an old resistance point, you have to have a catalyst to get through. Remember, people sold (didn't like) this stock at that peak level (around $5.50). And now it's approaching that level.
If there's a catalyst to break through, it will, but keep in mind that it has to be a pretty big catalyst. If there's not a huge change to the company, he'd probably look to sell really soon.
It is a really interesting mid cap of about $1 billion. It is very well managed and has made a couple of really strong acquisitions. It has increased its margins and revenue and upped its guidance last week. It is also profitable and the growth rate looks really good but the stock has lagged. Management has never strayed from their strategy and is going to grow this business and shift the Canadian market into the digitalized type of world.
Too small for his portfolios. In Canada, rolling up medical practices with a strategy of using technology to reduce administrative burden. In US, has a GI line, as well as virtual mental health and women's care; may spin off the latter two. Valuation ~40x forward PE, rich. He can't get behind that valuation, but progress will be interesting to watch.
Tends to spike on a few catalysts, then falls off if there's no follow through. His position isn't large. Good runway to analysts' price target. Building out clinical side of business and the SaaS side. Needs more catalysts. Wishes he'd traded it instead of invested.
(Analysts’ price target is $8.70)